BELLEROPHON would like to make a call for the process development and production in E. coli according to Good Manufacturing Practice (GMP) of a protein vaccine candidate to be used in toxicological and phase I studies. The subcontracting is expected in Q4 2015.
TRANSVAC: new vaccines faster
Welcome to TRANSVAC, a collaborative infrastructure project funded under the European Commission’s (EC) 7th Framework Programme (FP7). The project is the joint effort of leading European groups in the field of vaccine development, and is coordinated by the European Vaccine Initiative (EVI). TRANSVAC was designed in order to enhance European research and training and foster the seamless implementation of a permanent research infrastructure for early vaccine development in Europe.
In order to reach its ambitious goal, TRANSVAC carries out activities at various levels. On this website you can find out about how to benefit from TRANSVAC’s portfolio of activities, learn how to apply for access to the TRANSVAC’s high-quality Infrastructure Free Services and Paid Services, how to participate in the free Workshops on Animal Models or in the free Modular Course on Concepts on Vaccine Development. Finally, TRANSVAC looks to the future and is exploring the implementation of a road map towards a sustainable European vaccine development platform beyond TRANSVAC. This is done by the European Vaccine Development Stakeholder Working Groups.
The annual meeting of MVVC / MVVC 2 held in Oxford in March is mentioned in the EDCTP May news letter (page 6). Field trials of a new combination malaria vaccine, which are an integral part of the MVVC2 project, are funded by among others EDCTP.
Want to learn more about what EVI is doing, then join us for the 2015 Rendez-Vous on 9 December.
It is an increasing popular event, bringing together people from all corners of the scientific community, the European Commission and other like funders.